Terns Pharmaceuticals, Inc.
$0
0%
2026-07-22 10:57:00
www.ternspharma.com
NMS: TERN
Explore Terns Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.12 B
Current Price
$0
52W High / Low
$53.19 / $5.24
Stock P/E
—
Book Value
$8.96
Dividend Yield
—
ROCE
-10.92%
ROE
-20.02%
Face Value
—
EPS
$-1.03
Exp Qtr EPS
—
Sector
Healthcare
TERN — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $675.19 | 15.81 | $69.94 B | 0.56% | 10.23% | 14.32% | $821.11 / $541 | $295.71 |
| 3. | Revolution Medicines, Inc. | $183.29 | — | $38.94 B | — | -57.28% | -54.06% | $193.82 / $34 | $8.28 |
| 4. | Alnylam Pharmaceuticals, Inc. | $271.37 | 62.78 | $36.24 B | — | 14.33% | 98.29% | $495.55 / $266.27 | $5.96 |
| 5. | Roivant Sciences Ltd. | $34.96 | — | $33.71 B | — | -21.06% | -6.85% | $37 / $10.9 | $6.28 |
| 6. | Royalty Pharma plc | $58.42 | 40.45 | $33.47 B | 1.61% | 8.21% | 12.67% | $59.44 / $34.08 | $11.22 |
| 7. | Moderna, Inc. | $59.66 | — | $23.63 B | — | -29.7% | -36.73% | $85.6 / $22.28 | $21.95 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -27.6 M | -27.72 M | -27.38 M | -27.43 M | -25.95 M | — |
| Net Profit | -23.57 M | -24.64 M | -24.09 M | -23.91 M | -21.8 M | — |
| EPS in Rs | -0.2 | -0.21 | -0.21 | -0.21 | -0.19 | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -110.12 M | -101.87 M | -102.56 M | -62.03 M |
| Net Profit | -96.21 M | -88.85 M | -90.21 M | -60.34 M |
| EPS in Rs | -0.83 | -0.77 | -0.78 | -0.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.03 B | 363.93 M | 268.52 M | 287.03 M |
| Total Liabilities | 18.55 M | 18.06 M | 13.15 M | 10.08 M |
| Equity | 1.01 B | 345.87 M | 255.37 M | 276.94 M |
| Current Assets | 1.02 B | 362.11 M | 267.43 M | 285.19 M |
| Current Liabilities | 16.41 M | 15.65 M | 11.94 M | 8.47 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -82.18 M | -70.02 M | -67.39 M | -49.11 M |
| Investing CF | -298.04 M | -12.41 M | -37.99 M | -22.27 M |
| Financing CF | 743.51 M | 164 M | 41.95 M | 167.09 M |
| Free CF | -82.18 M | -70.06 M | -67.44 M | -49.38 M |
| Capex | — | -0.04 M | -0.05 M | -0.28 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 1.5% | -49.49% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.